These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21596683)

  • 21. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
    Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
    Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of lower respiratory tract infections in elderly].
    Iakovlev SV
    Ter Arkh; 1997; 69(12):57-63. PubMed ID: 9503539
    [No Abstract]   [Full Text] [Related]  

  • 23. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia.
    Pfaller MA; Mendes RE; Sader HS; Jones RN
    J Antimicrob Chemother; 2010 Nov; 65(11):2396-404. PubMed ID: 20846936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
    Nailor MD; Sobel JD
    Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin-resistant Enterococci. Prevalence and risk factors for fecal carriage in patients at tertiary care hospitals.
    El-Amin NM; Faidah HS
    Saudi Med J; 2011 Sep; 32(9):966-7. PubMed ID: 21894365
    [No Abstract]   [Full Text] [Related]  

  • 26. [Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance].
    Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):293-300. PubMed ID: 9265387
    [No Abstract]   [Full Text] [Related]  

  • 27. Vancomycin-resistant enterococcal infections.
    Murray BE
    N Engl J Med; 2000 Mar; 342(10):710-21. PubMed ID: 10706902
    [No Abstract]   [Full Text] [Related]  

  • 28. [Action in nosocomial pneumonia and severe skin and soft tissue infections. Linezolid in treatment].
    Bodmann KF
    Pharm Unserer Zeit; 2004; 33(1):38-41. PubMed ID: 14968711
    [No Abstract]   [Full Text] [Related]  

  • 29. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
    Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antibiotics for healthcare-associated pneumonia.
    Neuner EA; Ritchie DJ; Micek ST
    Semin Respir Crit Care Med; 2009 Feb; 30(1):92-101. PubMed ID: 19199191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy for hospital-acquired pneumonia.
    Liapikou A; Rosales-Mayor E; Torres A
    Expert Opin Pharmacother; 2014 Apr; 15(6):775-86. PubMed ID: 24579912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.
    Torres A; Rubinstein E; Corey GR; Stryjewski ME; Barriere SL
    J Antimicrob Chemother; 2014 Apr; 69(4):1119-26. PubMed ID: 24398339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
    Hegde SS; Janc JW
    Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consensus document on controversial issues for the treatment of hospital-associated pneumonia.
    Franzetti F; Antonelli M; Bassetti M; Blasi F; Langer M; Scaglione F; Nicastri E; Lauria FN; Carosi G; Moroni M; Ippolito G;
    Int J Infect Dis; 2010 Oct; 14 Suppl 4():S55-65. PubMed ID: 20863734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
    Liapikou A; Dimakou K; Toumbis M
    Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
    Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
    Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Teicoplanin. New treatment potentials for gram-positive infections in the hospital].
    Iakovlev SV
    Antibiot Khimioter; 1999; 44(2):3-7. PubMed ID: 10202550
    [No Abstract]   [Full Text] [Related]  

  • 38. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
    Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
    Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction: treatment of Gram-positive infections.
    Wise R
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii5-7. PubMed ID: 12797336
    [No Abstract]   [Full Text] [Related]  

  • 40. Emerging glycopeptide resistance in gram-positive organisms.
    von Gottberg A; Ferraz V; Dusé AG
    S Afr Med J; 2000 Nov; 90(11):1108-9. PubMed ID: 11196027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.